D'anna Cain
Family · Gainesville, GANPI 1538653829
Payments from drug & device makers
Across 279 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- AbbVie$586
- Novo Nordisk$585
- Lilly USA, LLC$427
- Pfizer$338
- GSK$263
- plus $1K from 22 others
What the payments were for
- Travel & lodging$1,56027%
- Food & beverage$4,28973%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 27 | $2,393 |
| AbbVie | 69 | $586 |
| Novo Nordisk | 54 | $585 |
| Lilly USA, LLC | 26 | $427 |
| Pfizer | 20 | $338 |
| GSK | 14 | $263 |
| AstraZeneca | 8 | $241 |
| Otsuka America Pharmaceutical, Inc. | 8 | $149 |
| Amarin Pharma, Inc. | 10 | $146 |
| Astellas Pharma US Inc | 8 | $142 |
| Corcept Therapeutics | 5 | $85 |
| Esperion Therapeutics, Inc. | 4 | $64 |
| Eisai Inc. | 3 | $43 |
| Xeris Pharmaceuticals, Inc. | 3 | $42 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Mylan Specialty L.p. | 2 | $38 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Abbott | 2 | $28 |
| Nevro Corp. | 2 | $24 |
| Pacira Pharmaceuticals Incorporated | 1 | $24 |
| Tris Pharma Inc | 1 | $23 |
| Boehringer Ingelheim | 1 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $20 |
| Boston Scientific | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$1,128
- INPEN SMART INSULIN DELIVERY SYSTEM$303
- MINIMED 780G$277
- AIRSUPRA$114
- Ozempic$110
How this compares
$5,850 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $141,767 |
| EliquisApixaban | 49 | $58,915 |
| JardianceEmpagliflozin | 53 | $51,030 |
| MounjaroTirzepatide | 32 | $38,090 |
| TradjentaLinagliptin | 34 | $36,688 |
| FarxigaDapagliflozin Propanediol | 37 | $35,475 |
| TrulicityDulaglutide | 35 | $35,379 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $35,281 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $24,984 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $22,323 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $19,369 |
| Novolog FlexpenInsulin Aspart | 58 | $18,638 |
| LinzessLinaclotide | 13 | $18,023 |
| JanuviaSitagliptin Phosphate | 20 | $17,799 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $13,459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $585 | $141,76799 claims |
| Boehringer IngelheimJardiance, Tradjenta | $23 | $87,71887 claims |
| Lilly USA, LLCMounjaro, Trulicity | $427 | $73,46967 claims |
| PfizerEliquis | $338 | $58,91549 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $263 | $55,75594 claims |
| AstraZenecaFarxiga, Symbicort | $241 | $39,23853 claims |
| AbbVieLinzess, Synthroid | $586 | $23,34158 claims |
| Sanofi-aventis U.S. LLCLantus | $28 | $1,67811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Gainesville
- Kristina JamesGainesville$16K
- Leigh DayGainesville$16K
- Jeanette PirkleGainesville$15K
- Jennifer ButlerGainesville$14K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.